Alembic Pharma Receives USFDA Tentative Approval for Larotrectinib

Alembic Pharmaceuticals Limited has secured tentative approval from the United States Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Larotrectinib capsules in 25 mg and 100 mg strengths. This development marks a significant step for the company in expanding its specialized oncology portfolio for the U.S. healthcare market.

The approved capsules are therapeutically equivalent to the reference listed drug product, Vitrakvi, marketed by Bayer HealthCare Pharmaceuticals Inc. Larotrectinib is a specialized kinase inhibitor indicated for the treatment of adult and pediatric patients with solid tumors that harbor a neurotrophic receptor tyrosine kinase (NTRK) gene fusion.

Advancing Oncology Treatment Access

Larotrectinib is classified as a "tumor-agnostic" or histology-independent therapy. Unlike traditional treatments that target cancer based on where it originates in the body, this medication targets specific genetic changes within the cancer cells. It is specifically intended for patients whose cancer is metastatic, for whom surgical resection is likely to result in severe morbidity, or who have no satisfactory alternative treatment options.

According to the USFDA regulatory filings, Alembic is the first applicant to have filed its ANDA for these specific strengths of Larotrectinib, containing a Paragraph IV certification under the Hatch-Waxman Act. This status may make the company eligible for 180 days of generic marketing exclusivity upon final approval.

Official Corporate Response

In a formal disclosure to the National Stock Exchange of India (NSE), Alembic Pharmaceuticals confirmed the receipt of the tentative approval. The company stated that it remains committed to providing affordable, high-quality generic options for patients requiring complex cancer care.

"The tentative approval for Larotrectinib underscores our ongoing efforts to strengthen our presence in the U.S. generic space, particularly in the therapeutic area of oncology," representatives for the firm noted in the filing.

Why It Matters

For patients and healthcare providers, the introduction of a generic alternative for a specialized therapy like Larotrectinib is highly significant. With an estimated market size of US$ 91 million for the twelve months ending March 2026—as reported by IQVIA—this drug represents a high-value niche in the pharmaceutical sector. By securing this tentative approval, Alembic positions itself to potentially reduce the cost burden for patients once final regulatory clearances are granted, providing more accessible options for managing rare, gene-fusion-driven solid tumors.

Key Facts at a Glance

• Product: Larotrectinib Capsules (25 mg and 100 mg).

• Regulatory Status: Tentative approval granted by the USFDA.

• Market Opportunity: Estimated annual market size of approximately US$ 91 million (as of March 2026).

• Exclusivity Potential: As a first-to-file applicant with a Paragraph IV certification, the company may be eligible for 180 days of generic market exclusivity.

• Clinical Use: Targeted therapy for adult and pediatric patients with solid tumors featuring NTRK gene fusions.

FAQ

What is Larotrectinib used for? Larotrectinib is a targeted kinase inhibitor used to treat solid tumors that have specific genetic changes (NTRK gene fusion) and have spread or cannot be treated with surgery.

What does "tentative approval" mean? It means the USFDA has concluded that the drug product meets all required quality, safety, and efficacy standards for approval, but it cannot be marketed in the U.S. until outstanding issues—such as patent protections or exclusivity periods—are resolved.

When will the product be available? The commercial launch date depends on the outcome of final regulatory processes and, where applicable, the resolution of ongoing patent litigation.

Source:

• Alembic Pharmaceuticals Limited - Regulatory Filing (NSE)

• U.S. Food & Drug Administration (USFDA)

• IQVIA Market Data